Kura Oncology(US:KURA) ZACKS·2025-11-04 13:46Core Viewpoint - Kura Oncology reported a quarterly loss of $0.85 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.57, marking a significant earnings surprise of -49.12% [1][2] Financial Performance - The company posted revenues of $20.75 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 75.72%, compared to zero revenues a year ago [2] - Over the last four quarters, Kura Oncology has surpassed consensus EPS estimates only once [2] Stock Performance - Kura Oncology shares have increased by approximately 12.2% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $102.93 million, and for the current fiscal year, it is -$2.07 on revenues of $154.92 million [7] - The trend of estimate revisions for Kura Oncology was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Kura Oncology belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable industry outlook [8]